cdmo.directory
← Compare landing

Genevoyager (Wuhan) Co., Ltd. vs ProBio

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/genevoyager-2/probio

CategoryGenevoyager (Wuhan) Co., Ltd.ProBio
Listed sitebothboth
SummaryLeading CRO/CDMO provider specializing in viral vectors, proteins, and vaccines with proprietary AAV manufacturing technology and cGMP-grade facilities operational since October 2023.ProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.
Services
  • Translational Research
  • Analytical Method Development & Validation
  • Regulatory Affairs
  • Analytical Method Development & Validation
  • ICH Stability Studies
  • In Vitro Pharmacology
  • Protein Engineering
  • Bioanalysis
  • Flow Cytometry Services
  • Immunogenicity Assays (ADA / NAb)
Modalities
  • Biologics (Other)
  • Vaccine
  • AAV / Viral Vector Platform
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • AAV / Viral Vector Platform
IndicationsData not yet provided.
  • Infectious Disease
Locations
  • Headquarters & cGMP Facility, Wuhan, Jiangxia District, China
  • United States, United States
  • Netherlands, Netherlands
  • South Korea, South Korea
  • Hong Kong, Hong Kong, China
  • Shanghai, Shanghai, China
  • Nanjing, Nanjing, China
Certifications
  • China · Identifier: High-tech Enterprise (高新技术企业)
  • FDA · Identifier: US Food and Drug Administration
  • EMA · Identifier: European Medicines Agency
  • NMPA · Identifier: National Medical Products Administration
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.